Scarica l'app Stockscreener
16.11
1.77%
0.28
Dopo l'orario di chiusura:
16.14
0.03
+0.19%
Precedente Chiudi:
$15.83
Aprire:
$16.46
Volume 24 ore:
4.99M
Relative Volume:
4.12
Capitalizzazione di mercato:
$1.42B
Reddito:
$139.71M
Utile/perdita netta:
$-209.36M
Rapporto P/E:
-6.2442
EPS:
-2.58
Flusso di cassa netto:
$-160.60M
1 W Prestazione:
-26.03%
1M Prestazione:
-18.26%
6M Prestazione:
-20.60%
1 anno Prestazione:
+5.50%
Intervallo 1D:
$15.73
$16.90
Intervallo di 1 settimana:
$15.50
$17.87
Portata 52W:
$14.96
$25.34
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
Nome
Syndax Pharmaceuticals Inc
Settore
Industria
Telefono
781-419-1400
Indirizzo
35 GATEHOUSE DRIVE, WALTHAM, MA
Confronta SNDX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| SNDX | 16.11 | 1.42B | 139.71M | -209.36M | -160.60M | -2.58 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-01-31 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| 2023-12-22 | Iniziato | Mizuho | Buy |
| 2023-10-25 | Iniziato | BofA Securities | Buy |
| 2023-10-11 | Iniziato | Goldman | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Outperform |
| 2023-07-11 | Iniziato | Guggenheim | Buy |
| 2023-04-17 | Ripresa | BTIG Research | Buy |
| 2023-01-31 | Iniziato | Stifel | Buy |
| 2023-01-03 | Iniziato | JP Morgan | Overweight |
| 2022-07-28 | Ripresa | B. Riley Securities | Buy |
| 2022-04-11 | Iniziato | H.C. Wainwright | Buy |
| 2022-02-15 | Iniziato | Goldman | Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-05-25 | Iniziato | Citigroup | Buy |
| 2021-02-18 | Iniziato | B. Riley Securities | Buy |
| 2020-12-03 | Iniziato | Stifel | Buy |
| 2020-05-22 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-05-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-05-18 | Downgrade | Citigroup | Buy → Neutral |
| 2020-05-11 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-13 | Reiterato | H.C. Wainwright | Buy |
| 2019-03-08 | Reiterato | H.C. Wainwright | Buy |
| 2019-01-04 | Iniziato | Robert W. Baird | Outperform |
| 2018-01-05 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2017-03-16 | Iniziato | FBR & Co. | Outperform |
| 2017-03-02 | Iniziato | Instinet | Buy |
| 2016-10-07 | Iniziato | Guggenheim | Buy |
| 2016-03-28 | Iniziato | Citigroup | Buy |
| 2016-03-28 | Iniziato | JMP Securities | Mkt Outperform |
| 2016-03-28 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Syndax Pharmaceuticals Inc Borsa (SNDX) Ultime notizie
Syndax Pharmaceuticals Leukemia Drug Wins a First-in-Class FDA Approval - MedCity News
Syndax Scores First-Mover Advantage With Approval Of Menin Inhibitor For Leukemia - Citeline
Syndax secures FDA OK for new kind of leukemia drug - BioPharma Dive
First Week of July 2025 Options Trading For Syndax Pharmaceuticals (SNDX) - Nasdaq
HC Wainwright Issues Positive Forecast for Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price - MarketBeat
FDA approves Syndax’s Revuforj to treat leukaemia - Yahoo Finance
Syndax gets FDA okay for first-in-class leukaemia drug - pharmaphorum
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Rating Upgraded by StockNews.com - Defense World
Syndax Pharmaceuticals (NASDAQ:SNDX) Raised to Hold at StockNews.com - MarketBeat
US FDA approves Syndax's blood cancer drug - Reuters.com
Syndax's Revuforj Wins FDA Approval as First Menin Inhibitor for Acute Leukemia | SNDX Stock News - StockTitan
Simplify Asset Management Inc. Buys 46,992 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
(SNDX) Investment Analysis and Advice - Stock Traders Daily
Syndax Pharmaceuticals' SWOT analysis: biotech stock poised for growth amid FDA approvals By Investing.com - Investing.com South Africa
Syndax’s stock sinks by 25% despite AML trial meeting primary endpoint - Pharmaceutical Technology
Syndax Pharmaceuticals' SWOT analysis: biotech stock poised for growth amid FDA approvals - Investing.com UK
Syndax’s revumenib meets primary results in AML trial - Yahoo Finance
Syndax shares slide despite pivotal trial success - The Pharma Letter
Syndax: Fall On NPM1m AML Data Of Revumenib Creates Buy Opportunity (NASDAQ:SNDX) - Seeking Alpha
Syndax Pharmaceuticals Inc Still Hasn’t Convinced Analysts? - Stocks Register
Syndax Pharmaceuticals Stock Falls After Data From Mid-Stage Study Of Revumenib In Form Of Blood Cancer - AOL
Syndax falls after mid-stage data for leukemia drug - MSN
Syndax's Revumenib Trial Hits Key Endpoint with 47% Response Rate in AML Treatment | SNDX Stock News - StockTitan
Syndax Pharmaceuticals (NASDAQ:SNDX) Given New $47.00 Price Target at HC Wainwright - Defense World
Creative Planning Has $318,000 Stock Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World
HC Wainwright Analysts Increase Earnings Estimates for SNDX - Defense World
Wellington Management Group LLP's Strategic Reduction in Syndax Pharmaceuticals Inc - GuruFocus.com
HC Wainwright Has Bullish Outlook for SNDX FY2024 Earnings - MarketBeat
Analysts Are Updating Their Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Estimates After Its Third-Quarter Results - Yahoo Finance
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
The Goldman Sachs Group Forecasts Strong Price Appreciation for Syndax Pharmaceuticals (NASDAQ:SNDX) Stock - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Syndax Pharmaceuticals outlines Q3 2024 progress By Investing.com - Investing.com Canada
Syndax and Royalty Pharma finalize $350 million deal | Pharmaceutical | The Pharmaletter - The Pharma Letter
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Syndax Pharmaceuticals Inc (SNDX) Q3 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Syndax Pharmaceuticals Inc (SNDX) Q3 2024 Earnings Call Highligh - GuruFocus.com
Syndax Pharmaceuticals: Key Pipeline Developments and Financial Update - TipRanks
Finance Watch: Syndax Raises $350m, KalVista Gets $100m In Royalty Deals - Citeline
Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Syndax: Q3 Earnings Snapshot - San Francisco Chronicle
Syndax Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Syndax Pharma Secures FDA Approval for Niktimvo Despite $84.1M Q3 Loss | SNDX Stock News - StockTitan
SNDXSyndax Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Investors reevaluate this year’s obesity darling - STAT
Syndax Pharma to Present Revumenib & Niktimvo Updates at ASH 2024 Investor Event | SNDX Stock News - StockTitan
Syndax's Niktimvo Achieves 75% Response Rate in Pivotal GVHD Trial, New Data Shows | SNDX Stock News - StockTitan
Syndax agrees funding with Royalty Pharma for Niktimvo US sales - Yahoo Finance
Royalty Pharma plc and Syndax Pharmaceuticals Enter into $350 Million Royalty Funding Agreement for Niktimvo - Marketscreener.com
Syndax secures $350 million in royalty funding from Royalty Pharma By Investing.com - Investing.com Canada
Syndax Pharmaceuticals Inc Azioni (SNDX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.66%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):